EZZ Life Science Holdings Ltd (EZZ) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of EZZ Life Science Holdings Ltd A$0.56, price A$0.42, upside +36.0%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch EZZ Life Science Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range A$0.2551 – A$4.83 · fair‑value band A$0.3189 – A$1.34 · the A$0.4150 price screens below the A$0.5643 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow EZZ Life Science Holdings in your weekly email
Every Wednesday you see whether EZZ Life Science Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products.
Show more
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consumer distribution through e-commerce store. The company provides health and wellness products under the EZZ brand. It also offers its products online. The company was incorporated in 2015 and is based in Lidcombe, Australia.
Stock analysis
EZZ Life Science Holdings Ltd (EZZ) currently trades at A$0.4150, while our model-based Fair Value estimate is A$0.5643, implying the stock looks roughly 26.5% undervalued today.
Show more
Valuation
Bull case: the Earnings-Based group reads highest at a median of A$5.01 per share, and 25 of the 26 models we run sit above the A$0.4150 price.
Bear case: the Asset-Based group reads lowest at A$0.4000, and 1 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: A$0.3189 (bear) to A$1.34 (bull), the price of A$0.4150 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
EZZ Life Science Holdings Ltd reported revenue of A$66.9M in FY2024 versus A$22.3M in FY2020, a compound +31.6%/yr. Reported net income was A$6.7M in FY2024, compounding +34.9%/yr from FY2020.
Key figures
Market cap A$23.3M (≈ $16.3M) · P/E ratio 6.9 · P/S ratio 0.70 · EPS (TTM) A$0.0600 · Dividend yield 4.8% · Net margin 10.1% · Return on equity 11.2% · Return on assets (EBIT) 25.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 87% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 36%, EZZ screens cheaper than that median.
Fair Value models
Bear A$0.3189Fair Value A$0.5643Bull A$1.34
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (A$0.0400 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.0%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+36.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+31.7%
Dividend (yield on the price)4.8%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 15%
2024 sits 71% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Compare EZZ Life Science Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Above median
Fair Value upside+36% · Top 25%
Profitability
Return on equity (TTM)11% · Top 25%
Return on assets11% · Top 25%
Net margin (TTM)5% · Below median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth−18% · Bottom 25%
Dividend yield (TTM)4.8% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EZZ Life Science Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EZZ
Frequently asked questions
Is EZZ Life Science Holdings Ltd (EZZ) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.5643 versus a price of A$0.4150, about +36% upside (undervalued).
What is the fair value of EZZ?
Our model-based fair value for EZZ Life Science Holdings Ltd is A$0.5643 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.4150.
What is the quality score of EZZ?
EZZ Life Science Holdings Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EZZ Life Science Holdings Ltd (EZZ)?
Our model-based price target is the fair value of A$0.5643 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario A$0.3189, optimistic scenario A$1.34. It is a calculation from audited fundamentals, not an analyst target.
What is the EZZ Life Science Holdings Ltd stock forecast for 2026?
Our models put fair value at A$0.5643, about +36% upside versus a price of A$0.4150 (undervalued). Cautious scenario A$0.3189, optimistic scenario A$1.34. The calculation is refreshed regularly with new filings.
What is the revenue of EZZ Life Science Holdings Ltd (EZZ)?
EZZ Life Science Holdings Ltd reported trailing-twelve-month revenue of about A$61.4M (latest available figure, as of Sep 23, 2026).
Does EZZ Life Science Holdings Ltd pay a dividend?
EZZ Life Science Holdings Ltd currently shows a dividend yield of about 4.82% relative to its recent price (as of Sep 23, 2026).
What growth is priced into EZZ Life Science Holdings Ltd (EZZ)?
For today's price to be fair in a discounted-cash-flow model, EZZ Life Science Holdings Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +31.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of EZZ use?
Our models discount EZZ Life Science Holdings Ltd at 9.3 %: a base by market capitalisation (nano), damped by beta 0.91, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EZZ Life Science Holdings Ltd that is less than minus 40 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has EZZ Life Science Holdings Ltd (EZZ) delivered so far?
Over the past 5 years revenue at EZZ Life Science Holdings Ltd grew +31.0 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EZZ Life Science Holdings Ltd (EZZ) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into EZZ Life Science Holdings Ltd (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EZZ Life Science Holdings Ltd (EZZ)?
The free-cash-flow yield on the price is 21.32 %: that much free cash flow EZZ Life Science Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EZZ Life Science Holdings Ltd (EZZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EZZ Life Science Holdings Ltd it is A$0.5643 per share (as of Sep 23, 2026), against a price of A$0.4150. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is EZZ Life Science Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, EZZ trades below its calculated fair value: price A$0.4150, fair value A$0.5643, a gap of about +36% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EZZ?
No. The price is what the market pays today (A$0.4150); the fair value is what the company's own numbers justify (A$0.5643). For EZZ Life Science Holdings Ltd the two are A$0.1493 per share apart. That gap is exactly why we show both numbers side by side.
How much is EZZ Life Science Holdings Ltd worth?
The market values EZZ Life Science Holdings Ltd at about A$23.3M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.4150; our models calculate a fair value of A$0.5643 per share.
What do the bullish and bearish scenarios say about EZZ?
Our models span a range for EZZ Life Science Holdings Ltd: cautious scenario A$0.3189, base A$0.5643, optimistic A$1.34 per share (as of Sep 23, 2026, price A$0.4150). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EZZ?
EZZ Life Science Holdings Ltd trades at a price-to-earnings ratio of 6.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$0.5643 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.3.
How solid is the balance sheet of EZZ Life Science Holdings Ltd (EZZ)?
Balance-sheet figures for EZZ Life Science Holdings Ltd (as of Sep 23, 2026): return on equity 11.2%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is EZZ from its 52-week high?
EZZ Life Science Holdings Ltd trades at A$0.4150, about 87% below its 52-week high of A$3.29 and 14% above the low of A$0.3650 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.5643 is for.
Which stocks are comparable to EZZ Life Science Holdings Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EZZ Life Science Holdings Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.4150, calculated fair value A$0.5643 (+36%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EZZ calculated?
We run EZZ Life Science Holdings Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.5643, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. EZZ Life Science Holdings Ltd currently trades 36 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EZZ Life Science Holdings Ltd (EZZ)?
The closing price on Sep 24, 2026 was A$0.4150. Our model-based fair value is A$0.5643, about +36% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EZZ Life Science Holdings Ltd right now?
The model range is unusually wide (A$0.3189 to A$1.34). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of EZZ Life Science Holdings Ltd
How large is the market capitalisation of EZZ Life Science Holdings Ltd (EZZ)?
The market capitalisation of EZZ Life Science Holdings Ltd is A$23.3M (≈ $16.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EZZ Life Science Holdings Ltd (EZZ)?
The price-to-sales ratio of EZZ Life Science Holdings Ltd is 0.70 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EZZ Life Science Holdings Ltd (EZZ)?
Earnings per share at EZZ Life Science Holdings Ltd are A$0.0600 (price ÷ EPS = P/E 6.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of EZZ Life Science Holdings Ltd (EZZ)?
The dividend yield of EZZ Life Science Holdings Ltd is 4.8% (payout 33.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EZZ Life Science Holdings Ltd (EZZ)?
The net margin of EZZ Life Science Holdings Ltd is 10.1% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EZZ Life Science Holdings Ltd (EZZ)?
The return on equity (ROE) of EZZ Life Science Holdings Ltd is 11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EZZ Life Science Holdings Ltd (EZZ)?
On an EBIT basis the return on assets of EZZ Life Science Holdings Ltd is 25.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EZZ Life Science Holdings Ltd (EZZ)?
The operating margin of EZZ Life Science Holdings Ltd is −0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EZZ Life Science Holdings Ltd (EZZ)?
Revenue at EZZ Life Science Holdings Ltd is growing −18.1% versus a year earlier (3y avg +64.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EZZ Life Science Holdings Ltd (EZZ)?
Earnings per share at EZZ Life Science Holdings Ltd are growing −44.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does EZZ Life Science Holdings Ltd (EZZ) hold?
EZZ Life Science Holdings Ltd holds more cash than debt, A$20.5M net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch EZZ Life Science Holdings Ltd in the live analysis
One click puts EZZ Life Science Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
